



SOCIETA' ITALIANA  
DI VIROLOGIA

ITALIAN SOCIETY  
FOR VIROLOGY

# 7<sup>th</sup> National Congress of the Italian Society for Virology

*One Virology One Health*

**Brescia**  
**June 25-27, 2023**

Centro Congressi Paolo VI  
Via Gezio Calini, 30

[www.congressosiv-isv.com](http://www.congressosiv-isv.com)



**ABSTRACT BOOK**

## STRIGOLACTONES AS BROAD-SPECTRUM ANTIVIRALS AGAINST $\beta$ -CORONAVIRUSES THROUGH TARGETING THE MAIN PROTEASE M<sup>pro</sup>

G. Bajetto<sup>4</sup>, M. Biolatti<sup>1</sup>, M. Blangetti<sup>2</sup>, M. Baggieri<sup>3</sup>, A. Marchi<sup>3</sup>, S. Gioacchini<sup>3</sup>, D. Arnodo<sup>2</sup>, P. Bucci<sup>3</sup>, R. Fioravanti<sup>3</sup>, M. Kojouri<sup>3</sup>, M. Bersani<sup>5</sup>, G. D'Arrigo<sup>5</sup>, L. Siragusa<sup>6,7</sup>, S. Ghinato<sup>2</sup>, M. De Andrea<sup>1,4</sup>, F. Gugliesi<sup>1</sup>, C. Albano<sup>1</sup>, S. Pasquero<sup>1</sup>, I. Visentin<sup>8</sup>, E. D'Ugo<sup>3</sup>, F. Esposito<sup>9</sup>, P. Malune<sup>9</sup>, E. Tramontano<sup>9</sup>, C. Prandi<sup>2</sup>, F. Spyraakis<sup>5</sup>, F. Magurano<sup>3</sup>, V. Dell'Oste<sup>1</sup>

<sup>1</sup> Department of Public Health and Pediatric Sciences, University of Turin, Italy

<sup>2</sup> Department of Chemistry, University of Turin, Italy

<sup>3</sup> Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy

<sup>4</sup> Center for Translational Research on Autoimmune and Allergic Disease-CAAD, Novara, Italy

<sup>5</sup> Department of Drug Science and Technology, University of Turin, Italy

<sup>6</sup> Molecular Discovery Ltd., Kinetic Business Centre, Elstree, Borehamwood, Hertfordshire, United Kingdom

<sup>7</sup> Molecular Horizon s.r.l., Bettona, Perugia, Italy

<sup>8</sup> Department of Agricultural, Forestry, and Food Sciences, University of Turin, Grugliasco, Turin, Italy

<sup>9</sup> Department of Life and Environmental Sciences, University of Cagliari, Italy

**Aim of the Study:** The current SARS-CoV-2 pandemic and the likelihood that new coronavirus strains will emerge in the immediate future point out the urgent need to identify new pan-coronavirus inhibitors. Strigolactones (SLs) are a class of plant hormones with multifaceted activities whose role in plant-related fields has been extensively explored. Recently, we proved that SLs also exert an antiviral activity toward herpesviruses, such as human cytomegalovirus (HCMV). Based on this background, this work aimed to ascertain whether SLs might constitute a new class of broad-spectrum compounds against  $\beta$ -coronaviruses ( $\beta$ -CoVs).

**Methods used:** We employed two indole-based SL analogs, named THEGO and EDOTEGO. We assessed the antiviral activity of the compounds against SARS-CoV-2 and the common cold human coronavirus HCoV-OC43, as prototypes of  $\beta$ -CoVs by standard plaque assay on VERO-E6 and MRC-5 cells, respectively. By using FLAP implemented in BiOGPS, we then investigate which might be the target of the analyzed SLs; we performed a docking simulation on all the available structures of SARS-CoV-2 proteins present in the Protein Data Bank, and among the highest-scored pockets we noticed the presence of the main protease (M<sup>pro</sup>) orthosteric site. Therefore, with Gold, we performed a more accurate docking simulation between the compounds and the M<sup>pro</sup> binding site to obtain ligand poses, and with Glide we simulated a covalent docking to obtain potential adducts. In the end, to strengthen the computational results, we tested the effect of EDOTEGO and THEGO on SARS-CoV-2 M<sup>pro</sup> activity using an *in-vitro* biochemical assay based on Fluorescence Resonance Energy Transfer (FRET).

**Results and Conclusions:** Here we show that the synthetic SLs THEGO and EDOTEGO impair  $\beta$ -CoVs replication, including SARS-CoV-2 and HCoV-OC43. Interestingly, *in-silico* simulations suggest the binding of SLs in the SARS-CoV-2 main protease (M<sup>pro</sup>) active site, and this was further confirmed by an *in-vitro* activity assay. Overall, our results highlight the potential efficacy of SLs as broad-spectrum antivirals against  $\beta$ -CoVs, which may provide the rationale for repurposing this class of hormones for the treatment of COVID-19 patients.